SLS Stock Halts Slide: AML Trial Combines SLS009 with Big Pharma Drugs
Sellas Life Sciences (SLS) shares rose after announcing a clinical trial for its SLS009 AML treatment in combination with drugs from ABBV, BMY, and RHHBY. The trial is based on a 2022 license from GenFleet.
Shares of Sellas Life Sciences (SLS) rose on Thursday, snapping a two-day losing streak, after the company announced a clinical trial for its drug SLS009 (formerly GFH009) in acute myeloid leukemia (AML), combining it with drugs from major pharmaceutical companies: AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Roche (RHHBY).
Trial Details
SLS009 is a selective CDK9 inhibitor that Sellas licensed from GenFleet in 2022, obtaining rights outside Greater China. The trial aims to evaluate the drug's efficacy when used alongside standard-of-care treatments from the three pharma giants.
Context
The announcement comes after two consecutive days of decline, suggesting investors viewed the partnership as a boost to the credibility of Sellas' clinical program. No financial details or trial timeline were disclosed.
What It Means for Investors
This move represents Sellas' attempt to strengthen its position in the competitive AML market. Success could open doors to broader partnerships or licensing deals, but clinical outcomes remain uncertain.
Frequently Asked Questions
Found this useful? Share it